# Vormatrigine PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vormatrigine

> The next catalyst for vormatrigine, sponsored by Praxis Precision Medicines, Inc. (PRAX), is its topline data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, month only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for vormatrigine?

The next catalyst for vormatrigine, sponsored by Praxis Precision Medicines, Inc. (PRAX), is its topline data readout, 2027. SEC Form 10-K: "POWER2 is enrolling patients, with completion expected in the second half of 2026 and topline results expected in 2027." [Calendar and source filings](https://sec-api.dev/pdufa/vormatrigine)

Source: SEC Form 10-K, accession 0001689548-26-000029, https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-05-07. Cite: https://sec-api.dev/pdufa/vormatrigine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | vormatrigine |
| Codes | PRAX-628 |
| Sponsor | Praxis Precision Medicines, Inc. (PRAX) https://sec-api.dev/companies/prax/catalysts |
| Indications | focal onset seizures or generalized epilepsy, treatment resistant fos |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2/3. Indication: treatment resistant FOS.
- First seen 2025-01-29, last confirmed 2025-05-02.
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000037): "oPraxis has also initiated the POWER1 Phase 2/3 registrational study of vormatrigine for treatment resistant FOS, with topline results anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000021): "◦Enrollment for the POWER1 Phase 2/3 registrational study in patients with treatment resistant FOS is progressing as planned, with topline results anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000021/a8-kexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000056): "In the near-term, we anticipate topline results for vormatrigine from the RADIANT study in epilepsy by mid-2025, and from the POWER1 study in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000056/praxisq12025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000037): "•Vormatrigine (PRAX-628) for Focal Onset Seizures and Generalized Epilepsy: The ENERGY program continues to progress, with multiple topline readouts expected in 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm
- SEC Form 10-Q (accession 0001689548-25-000058): "We have also initiated the POWER1 study, a double-blind, placebo-controlled, 12-week study in focal onset seizures, with topline results expected in the second half of 2025, and plan to begin enrollment in the POWER2 study, a third efficacy study, in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000058/prax-20250331.htm
- SEC Form 10-K (accession 0001689548-25-000040): "We anticipate topline results in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm
- SEC Form 10-K (accession 0001689548-25-000040): "We have also initiated the POWER1 study, a double-blind, placebo-controlled, 12-week study in focal onset seizures, with topline results expected in the second half of 2025, and plan to begin enrollment in the POWER2 study, a third efficacy study, in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm
- SEC Form 10-Q (accession 0001689548-25-000058): "The first efficacy study, RADIANT, is an open label eight-week study in patients with focal onset seizures or generalized epilepsy that is currently enrolling, with topline results expected by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000058/prax-20250331.htm
- SEC Form 10-K (accession 0001689548-25-000040): "We anticipate topline results by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm
- SEC Form 10-K (accession 0001689548-25-000040): "The first efficacy study, RADIANT, is an open label eight-week study in patients with focal onset seizures or generalized epilepsy that is currently enrolling, with topline results expected by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000040/prax-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000037): "oPraxis has initiated the RADIANT Phase 2, open-label, single-arm study for FOS and generalized epilepsy assessing seizure burden with vormatrigine treatment, with topline results expected by mid-year 2025." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/praxisye2024pr.htm

### Aug 2025: topline data readout

- Status: completed, positive. Date confidence: month. Indication: focal onset seizures or generalized epilepsy.
- First seen 2025-11-05, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001689548-25-000111): "In August 2025, we announced positive topline results from the first cohort of our first efficacy study, RADIANT, an open label study in patients with focal onset seizures or generalized epilepsy." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm

### 1H 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-02-19, last confirmed 2026-02-19.
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000028): ""The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm

### Q2 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-11-05, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "•The POWER1 Phase 3 study for FOS is on track for topline results in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000028): ""The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000110): "Recruitment completed for POWER1 study of vormatrigine in focal onset seizures, with topline results expected in 1H 2026" https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-25-000110): "For our vormatrigine program, following the positive results from the first cohort of the RADIANT study, we have now completed recruitment for POWER1 with expected readout in the first half of 2026, and POWER2 is underway and planning to be fully enrolled in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000110/praxisq32025pr.htm
- SEC Form 10-Q (accession 0001689548-26-000047): "For our POWER1 study, a double-blind, placebo-controlled, 12-week study in FOS, we expect to announce topline results in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000047/prax-20260331.htm
- SEC Form 10-K (accession 0001689548-26-000029): "We expect to announce topline results in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- SEC Form 10-K (accession 0001689548-26-000029): "For our POWER1 study, a double-blind, placebo-controlled, 12-week study in focal onset seizures, we expect to announce topline results in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- SEC Form 10-Q (accession 0001689548-25-000111): "We have completed recruitment of the POWER1 study, a double-blind, placebo-controlled, 12-week study in focal onset seizures, and expect to announce topline results in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1689548/000168954825000111/prax-20250930.htm

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-02-19, last confirmed 2026-05-07.
- SEC Form 10-K (accession 0001689548-26-000029): "POWER2 is enrolling patients, with completion expected in the second half of 2026 and topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- SEC Form 10-K (accession 0001689548-26-000029): "POWER2, our third efficacy study, is enrolling patients, with completion expected in the second half of 2026 and topline results expected in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000029/prax-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000049): "•POWER2, the second Phase 3 study for vormatrigine in FOS, continues to progress towards completion in the second half of 2026 with topline results anticipated in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/praxisq12026pr.htm
- Press release filed with the SEC (EX-99) (accession 0001689548-26-000028): "•POWER2, the second Phase 3 study for vormatrigine in FOS, is enrolling patients, with completion expected in the second half of 2026 and topline results anticipated in 2027." https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vormatrigine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vormatrigine PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vormatrigine

```bibtex
@misc{secapidev_pdufa_vormatrigine_20261116,
  title        = {Vormatrigine PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vormatrigine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vormatrigine_20261116","title":"Vormatrigine PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vormatrigine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
